Arcus Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	100	247	258	117	112	383
Revenue Growth	-58.33%	-4.26%	120.51%	4.46%	-70.76%	391.03%
Cost of Revenue	473	523	448	340	288	257
Gross Profit	-373	-276	-190	-223	-176	126
Selling, General & Admin	102	110	120	117	104	72
Operating Expenses	102	110	120	117	104	72
Operating Income	-475	-386	-310	-340	-280	54
Interest Expense	-11	-8	-4	-2	-2	-
Interest & Investment Income	33	41	52	41	16	1
EBT Excluding Unusual Items	-453	-353	-262	-301	-266	55
Asset Writedown	-	-	-20	-	-	-
Pretax Income	-453	-353	-282	-301	-266	55
Income Tax Expense	-	-	1	6	1	2
Net Income	-453	-353	-283	-307	-267	53
Net Income to Common	-453	-353	-283	-307	-267	53
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	124	107	90	74	72	69
Shares Outstanding (Diluted)	124	107	90	74	72	74
Shares Change	23.52%	19.20%	21.76%	2.78%	-2.70%	35.04%
EPS (Basic)	-3.64	-3.29	-3.14	-4.15	-3.71	0.76
EPS (Diluted)	-3.64	-3.29	-3.14	-4.15	-3.71	0.71
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-466	-484	-176	-330	432	-282
Free Cash Flow Per Share	-3.75	-4.51	-1.95	-4.46	6.00	-3.81
Gross Margin	-	-111.74%	-73.64%	-190.60%	-157.14%	32.90%
Operating Margin	-475.00%	-156.28%	-120.15%	-290.60%	-250.00%	14.10%
Profit Margin	-453.00%	-142.91%	-109.69%	-262.39%	-238.39%	13.84%
Free Cash Flow Margin	-466.00%	-195.95%	-68.22%	-282.05%	385.71%	-73.63%
EBITDA	-465	-376	-300	-332	-274	58
EBITDA Margin	-	-152.23%	-116.28%	-283.76%	-244.64%	15.14%
D&A For EBITDA	10	10	10	8	6	4
EBIT	-475	-386	-310	-340	-280	54
EBIT Margin	-	-156.28%	-120.15%	-290.60%	-250.00%	14.10%
Effective Tax Rate	-	-	-	-	-	3.64%
Revenue as Reported	100	247	258	117	112	383

SEC Filings: 10-K · 10-Q